Loading

Veterans

  • by Paul Armentano, NORML Deputy Director May 8, 2018

    Medical marijuanaPatients enrolled in New York state’s medical cannabis program reduce their use of opioids and spend less money on prescription medications, according to data published online in the journal Mental Health Clinician.

    Investigators from the GPI Clinical Research in Rochester and the University of Buffalo assessed trends in patients’ medical cannabis and prescription drug use following their enrollment into the state’s marijuana access program.

    On average, subjects’ monthly analgesic prescription costs declined by 32 percent following enrollment, primarily due to a reduction in the use of opioid pills and fentanyl patches. “After three months treatment, medical cannabis improved [subjects’] quality of life, reduced pain and opioid use, and lead to cost savings,” authors concluded.

    The study’s findings are similar to those reported among enrollees in other states medical cannabis programs, including the experiences of patients in Illinois, Michigan, Minnesota, New Mexico, and elsewhere.

    The full text of the study, “Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis,” appears online here. NORML’s fact-sheet highlighting the relevant, peer-reviewed research specific to the relationship between cannabis and opioids is available online here.

  • by Paul Armentano, NORML Deputy Director April 18, 2018

    United States Rep. Timothy Waltz (D-MN), along with over 30 bipartisan co-sponsors, has introduced legislation, HR 5520: The VA Medicinal Cannabis Research Act of 2018, to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans.

    The legislation states: “In carrying out the responsibilities of the Secretary of Veterans Affairs, … the Secretary may conduct and support research relating to the efficacy and safety of forms of cannabis … on the health outcomes of covered veterans diagnosed with chronic pain, post-traumatic stress disorder, and other conditions the Secretary determines appropriate.”

    According to nationwide survey data compiled by The American Legion, 39 percent of respondents affirmed that they “know a veteran” who is using the plant medicinally. Twenty-two percent of respondents said they themselves “use cannabis to treat a mental or physical condition.” Yet, VA Secretary David Shulkin has consistently rejected calls from veterans groups and lawmakers to study the use of cannabis among military veterans.

    Passage of HR 5520 explicitly authorizes “the Secretary to conduct and support research on the efficacy and safety of medicinal cannabis.”

    Representative Walz, who is the ranking member of the House VA committee, said: “While we know cannabis can have life-saving effects on veterans suffering from chronic pain or PTSD, there has been a severe lack of research studying the full effect of medicinal cannabis on these veterans. Simply put, there is no department or organization better suited to conduct this critically important research than VA, and there will never be a better time to act.”

    Please click here to urge your federal lawmakers to support HR 5520: The VA Medicinal Cannabis Research Act of 2018.

  • by Paul Armentano, NORML Deputy Director October 30, 2017

    medical_mj_shelfMembers of the US House Committee on Veteran’s Affairs are demanding the Department of Veterans Affairs facilitate protocols to assess the efficacy of medical cannabis in veterans suffering from chronic pain and post-traumatic stress.

    Minnesota Democrat Tim Walz, along with nine other Democrat members of the Committee, authored an October 26, 2017 letter to VA Secretary David Shulkin stating: “[The] VA is uniquely situated to pursue research on the impact of medical marijuana on veterans suffering from chronic pain and PTSD given its access to world class researchers, the population it serves, and its history of overseeing and producing research resulting in cutting-edge medical treatments. … VA’s pursuit of research into the impact of medical marijuana on the treatment of veterans diagnosed with PTSD who are also experiencing chronic pain is integral to the advancement of health care for veterans and the nation. We ask VA to respond … with a commitment to the development of VHA-led research into this issue.”

    In September, representatives from The American Legion addressed a separate letter to VA Secretary Shulkin encouraging the VA assist in an ongoing, FDA-approved clinical trial assessing the safety and efficacy of various strains of cannabis in veterans with PTSD. To date, the VA has refused to assist in patient recruitment for the trial. The VA has yet to publicly respond to the Legion’s letter.

    Survey data finds that military veterans report using cannabis therapeutically at rates far higher than the do those in the general population, and that many are already using it as an alternative to conventional medications in the treatment of pain and post-traumatic stress.

  • by Carly Wolf, NORML Political Associate October 6, 2017

    The American Legion has been calling on the federal government for over a year – specifically the Veterans Affairs Department – to support research into the therapeutic benefits of cannabis in treating veterans with PTSD.

    Many veterans have told both the Legion and NORML that they have been able to eliminate or reduce their dependency on other drugs, specifically opioids, by using cannabis.

    The Legion recently ramped up their efforts to convince VA Secretary Shulkin to expand research into the therapeutic and medicinal effects of cannabis by sending him a letter demanding for his direct involvement in making sure the medical marijuana study meets its goals.

    That letter was sent on September 19th. 17 days ago.

    Has Secretary Shulkin or the Dept. of Veterans Affairs responded? No. Have either even acknowledged receipt of the letter? To public knowledge, no.

    Why hasn’t Sec. Shulkin or the VA responded? Is he going to listen to the nation’s largest Veterans advocacy group? One that is pleading for help that our veterans so desperately need and deserve? Great question. The American Legion seems to be wondering the same thing.

    Screen Shot 2017-10-06 at 12.24.17 PM

    The Legion has been expressing their frustration on Twitter for Sec. Shulkin’s failure to act on this pressing issue.

    Screen Shot 2017-10-06 at 12.36.06 PM

     

    Screen Shot 2017-10-06 at 12.46.37 PM

    Secretary Shulkin is doing himself, our veterans, and to a larger extent, our nation, a huge disservice by not acknowledging the Legion’s cry for help and support.

    Join us in calling upon Secretary Shulkin to listen to the pleas of Veterans.

    Share one or more of the following tweets (and this blog on all of your accounts):

    Why hasn’t @SecShulkin responded to @AmericanLegion call for help? https://twitter.com/AmericanLegion/status/911576050043408384

    .@SecShulkin failure to act on this issue is hurting our veterans. @AmericanLegion
    https://twitter.com/AmericanLegion/status/913010589668188160

    RT to help the @AmericanLegion call upon @SecShulkin to take action on behalf of veterans

  • by Justin Strekal, NORML Political Director September 20, 2017

    legion_displayFor more than a year, The American Legion has been calling on the federal government – and specifically the Veterans Affairs Department – to support research into the therapeutic benefits of cannabis in treating veterans with PTSD.

    Many veterans, especially Iraq and Afghanistan combat veterans, have told both the Legion and NORML that they have been able to eliminate or reduce their dependency on other drugs, specifical opioids.

    Now, the Legion is ramping up their efforts to convince VA Secretary Shulkin to expand research into the therapeutic and medicinal effects of cannabis.

    In a letter sent yesterday and released publicly today, they state:

    Dear Mr. Secretary:

    For more than a year, the American Legion has called on the federal government to support and enable scientific research to clinically confirm the medicinal value of cannabis. The National Academy of Medicine recently reviewed 10,000 scientific abstracts on the therapeutic value of cannabis and reached nearly 100 conclusions in a report issued earlier this year. As a two million member strong veteran service organization, our primary interest and advocacy is grounded in the wellbeing and improved health of our veterans, and specifically our service disabled veterans.

    The American Legion supports VA’s statutory medical research million and has donated millions of dollars toward expanding VA’s scientific research. VA innovation is widely championed for its breakthrough discoveries in medicine and has been recognized over the years with three Nobel Prizes for scientific work that has benefitted the world over.

    Your immediate attention in this important matter is greatly appreciated. We ask for your direct involvement to ensure this critical research is fully implemented.

    Sincerely,
    Denise H. Rohan
    National Commander

    This comes just one month after the Legion adopted a resolution calling on federal officials to expand veterans’ access to medical marijuana.

    NORML has documented the longitudinal data on how cannabis access is associated with reduced rates of opioid use and abuse, opioid-related hospitalizations, opioid-related traffic fatalities, and opioid-related overdose deaths

    You can read the full letter to VA urging cannabis research access here.

    Click here to send a message to your federal officials in support of HR 1820, the bipartisan Veterans Equal Access Act introduced by Congressional Cannabis Caucus Co-Chair Earl Blumenauer

    Earlier this year, a budget amendment that reflected the Veterans Equal Access Act’s language was introduced by Senator Daines (R-MT) and passed in the Senate Appropriations Committee and introduced by Rep. Blumenauer and blocked in the House Rules Committee. The amendments fate will likely be decided in a joint conference committee later this year.

Page 2 of 3123